Clinical trials: Retina Patients
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.
- Trial name
- NCT00908778
- Testing
- Vitreosolve
- Where
- 5 sites in India, Mexico
- Volunteers
- 160 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
Branch Retinal Vein Occlusion, Macular Edema
Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).
- Trial name
- BRAVE (NCT03108352)
- Testing
- Conbercept ophthalmic injection
- Where
- 31 sites in China
- Volunteers
- 255 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.
Choroideremia
"Natural History" Study of Choroideremia
The purpose of this study is to understand the rate of progression of all stages of choroideremia using a variety of assessments performed in the clinic including visual field measures, specialized photography of the eye and…
- Trial name
- NCT02994368
- Testing
- Observation
- Where
- 4 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- 4D Molecular Therapeutics
Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD).
- Trial name
- 4FRONT-2 (NCT07064759)
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Branch Retinal Vein Occlusion
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- NCT04667897
- Testing
- 601 1.25mg, Ranibizuman 0.5 mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age Related Macular Degeneration
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye…
- Trial name
- NCT07811726
- Testing
- NT-101 ophthalmic solution
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- NexThera Co., Ltd.
Age-Related Macular Degeneration
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD
The safety and comfort of repeated administrations of a topically-administered ophthalmic formulation of MC-1101 will be established through investigator assessments and subject reporting over a 3 day period.
- Trial name
- NCT01013376
- Testing
- MC-1101, Vehicle
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MacuCLEAR, Inc.
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in…
- Trial name
- RESPOND (NCT01135914)
- Testing
- ranibizumab, Laser
- Where
- 20 sites in Canada
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Leber Congenital Amaurosis
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
MGT005 is a natural history study to collect longitudinal prospective data from patients with Leber Congenital Amaurosis associated with defects in RPE65.
- Trial name
- NCT02714816
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- MeiraGTx UK II Ltd
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Diabetic Macular Edema
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS)…
- Trial name
- VISTA DME (NCT01363440)
- Testing
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Where
- 51 sites in United States
- Volunteers
- 466 people
- Sponsor
- Regeneron Pharmaceuticals
Alzheimer Disease
Retinal Metabolic Imaging of Alzheimer Patient
This research project concerns the evaluation of the Metabolic Hyperspectral Retinal Camera (MHRC), a novel medical instrument from Optina Diagnostics, for the detection of beta-amyloid plaques, a hallmark of Alzheimer's disease…
- Trial name
- NCT03420807
- Testing
- MHRC
- Where
- Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Age-Related Macular Degeneration
Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD
- Trial name
- ASaP (NCT00473928)
- Testing
- POT-4
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Potentia Pharmaceuticals, Inc.
Age-Related Macular Degeneration
First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration
The purpose of this first-in-human study is to assess the local ocular and systemic safety and tolerability of LHA510 eye drops when administered at various concentrations and dosing frequencies.
- Trial name
- NCT02076919
- Testing
- LHA510 Ophthalmic Suspension, LHA510 Vehicle
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Macular Degeneration
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
This is a prospective, observational, multi-center, study. The study will be conducted in approximately 12 ophthalmological clinics and practices throughout Greece.
- Trial name
- PERSEUS-GR (NCT02821247)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Greece
- Volunteers
- 119 people
- Sponsor
- Bayer